NZ521183A - Crystalline form of lopinavir - Google Patents

Crystalline form of lopinavir

Info

Publication number
NZ521183A
NZ521183A NZ521183A NZ52118301A NZ521183A NZ 521183 A NZ521183 A NZ 521183A NZ 521183 A NZ521183 A NZ 521183A NZ 52118301 A NZ52118301 A NZ 52118301A NZ 521183 A NZ521183 A NZ 521183A
Authority
NZ
New Zealand
Prior art keywords
lopinavir
solid state
peak
range
infrared spectrum
Prior art date
Application number
NZ521183A
Other languages
English (en)
Inventor
Daniel A Dickman
Sanjay Chemburkar
James J Fort
Rodger F Enry
David Lechuga-Ballesteros
Yuping Niu
William Orter
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ521183(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/793,536 external-priority patent/US6608198B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NZ521183A publication Critical patent/NZ521183A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ521183A 2000-03-30 2001-03-21 Crystalline form of lopinavir NZ521183A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53825700A 2000-03-30 2000-03-30
US09/793,536 US6608198B2 (en) 2000-03-30 2001-02-27 Crystalline pharmaceutical
PCT/US2001/009112 WO2001074787A2 (en) 2000-03-30 2001-03-21 Crystalline pharmaceutical

Publications (1)

Publication Number Publication Date
NZ521183A true NZ521183A (en) 2004-03-26

Family

ID=27065762

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ521183A NZ521183A (en) 2000-03-30 2001-03-21 Crystalline form of lopinavir

Country Status (22)

Country Link
EP (1) EP1268442A2 (bg)
JP (1) JP2003529592A (bg)
KR (1) KR100773258B1 (bg)
CN (2) CN1330639C (bg)
AR (2) AR033360A1 (bg)
AU (3) AU2001250920B2 (bg)
BG (1) BG107165A (bg)
BR (1) BR0109433A (bg)
CA (1) CA2403635A1 (bg)
CZ (1) CZ20023529A3 (bg)
HU (1) HUP0302675A3 (bg)
IL (1) IL151551A0 (bg)
MX (1) MXPA02009559A (bg)
MY (1) MY128296A (bg)
NO (1) NO325005B1 (bg)
NZ (1) NZ521183A (bg)
PE (1) PE20011232A1 (bg)
PL (1) PL359727A1 (bg)
SA (2) SA06270303B1 (bg)
SK (1) SK14832002A3 (bg)
TW (1) TWI284640B (bg)
WO (1) WO2001074787A2 (bg)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2010089753A2 (en) * 2009-02-06 2010-08-12 Hetero Research Foundation Novel polymorphs of lopinavir
WO2011025849A1 (en) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis c virus
CN112830899A (zh) * 2021-01-18 2021-05-25 合肥华方医药科技有限公司 一种洛匹那韦新晶型及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound

Also Published As

Publication number Publication date
JP2003529592A (ja) 2003-10-07
SA06270303B1 (ar) 2009-08-02
TWI284640B (en) 2007-08-01
HUP0302675A2 (hu) 2003-12-29
KR100773258B1 (ko) 2007-11-05
KR20030011807A (ko) 2003-02-11
WO2001074787A2 (en) 2001-10-11
NO20024679D0 (no) 2002-09-30
AU5092001A (en) 2001-10-15
AU2001250920B2 (en) 2006-06-29
CN101066952A (zh) 2007-11-07
PL359727A1 (en) 2004-09-06
WO2001074787A3 (en) 2002-02-07
NO325005B1 (no) 2008-01-14
AU2006222711A1 (en) 2006-10-19
BR0109433A (pt) 2004-08-10
AR049560A2 (es) 2006-08-16
SK14832002A3 (sk) 2003-02-04
PE20011232A1 (es) 2001-12-08
MY128296A (en) 2007-01-31
AR033360A1 (es) 2003-12-17
CN1330639C (zh) 2007-08-08
HUP0302675A3 (en) 2004-03-29
CA2403635A1 (en) 2001-10-11
IL151551A0 (en) 2003-04-10
EP1268442A2 (en) 2003-01-02
MXPA02009559A (es) 2003-05-21
SA01220270B1 (ar) 2006-11-14
NO20024679L (no) 2002-09-30
CN1422259A (zh) 2003-06-04
BG107165A (bg) 2003-07-31
CZ20023529A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
US8058433B2 (en) Crystalline pharmaceutical
US8884013B2 (en) Polymorphs of Dasatinib, preparation methods and pharmaceutical compositions thereof
TW200944508A (en) Novel solid forms of bendamustine hydrochloride
HUE028620T2 (en) Tetrahydroisoquinoline derivative salt and solvates
AU2006222711A1 (en) Crystalline pharmaceutical
AU2001250920A1 (en) Crystalline pharmaceutical
CN112094249B (zh) 磺胺甲噻二唑-糖精共晶及其制备方法与应用
CN106565699B (zh) 一种艾沙康唑硫酸盐晶体及其制备方法
ZA200206962B (en) Crystalline pharmaceutical.
AU767331B2 (en) Polymorphs of crystalline (2-benzhydryl-1-azabicyclo(2.2.2) oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as NK-1 receptor antagonists
KR20120060947A (ko) 신규 고체 물질 ｛［（2ｓ,5ｒ,8ｓ,11ｓ）-5-벤질-11-（3-구아니디노-프로필）-8-이소프로필-7-메틸-3,6,9,12,15-펜타옥소-1,4,7,10,13-펜타아자-시클로펜타데크-2-일］-아세트산｝ 및 이의 제조 방법
US11999750B2 (en) Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide
WO2023139313A1 (en) Novel sulfate salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist
CN105612160A (zh) 用作半胱氨酸蛋白酶抑制剂的N-[1-6-(乙炔基-3-氧代-六氢-呋喃并[3,2-b]吡咯-4-羰基)-3-甲基-丁基]-4-[5-氟-2-(4-甲基-哌嗪基)噻唑-4-基]-苯甲酰胺的盐的形式2结晶多晶型物
JP2021525230A (ja) ４−フェニルチアゾール誘導体の結晶形およびその調製方法

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 21 MAR 2021 BY THOMSON REUTERS

Effective date: 20131218

ASS Change of ownership

Owner name: ABBVIE INC., US

Effective date: 20140327

S43A Offer to surrender
S43 Surrender of patents according section 43 patents act

Effective date: 20200624